▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #448 by analyst upside · 2026-06-27
CCCC
C4 Therapeutics, Inc.
Healthcare · Market Cap $471M · P/E 0x
ANALYST PRICE TARGET
+213.0%
implied upside to consensus target
Current Price $4.26
Consensus Target $13.33
Bull Target $30.0
Bear Target $7.0
Analysts Covering 6
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
5
Hold
0
Sell
0
52-Week Low $1.4
52-Week High $4.6
YTD Return +120.7%
FUNDAMENTALS
Market Cap $471M
P/E Ratio (TTM) N/A
Forward P/E -4.1x
EPS (TTM) $-1.10
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $35M
Profit Margin -297.8%
52-WEEK RANGE
52-Week Low $1.4
52-Week High $4.6
Current Price $4.26
Bear Target $7.0
Bull Target $30.0
● Now $4.26 ● Target $13.33
TRADING DATA
Avg Volume 2.8M
YTD Return +120.7%
Analyst Count 6
Consensus Buy
Upside to Target +213.0%
Last Updated 2026-06-27

ANALYST SUMMARY

C4 Therapeutics, Inc. (CCCC) is currently trading at $4.26 with a Wall Street consensus price target of $13.33, implying potential upside of 213.0% over the next 12 months. 6 analysts currently cover CCCC, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $7.0.

CCCC operates in the Healthcare sector with a market capitalisation of $471M. The stock is up 120.7% year-to-date and is currently trading near the upper end of its 52-week range of $1.4 – $4.6.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ABEO +251.4%
Abeona Therapeutics Inc.
$320M · P/E 5.9x · Buy
NAGE +268.4%
Niagen Bioscience, Inc.
$272M · P/E 16.3x · Buy
PHAR +157.5%
Pharming Group N.V.
$942M · P/E 70.2x · Buy
ZVRA +106.3%
Zevra Therapeutics, Inc.
$799M · P/E 6.6x · Buy
CRMD +93.6%
CorMedix Inc.
$616M · P/E 3.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CCCC, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Evercore ISI Group — Reiterated
Outperform → Outperform 2026-06-01 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-02-27 Building track record
Brookline Capital — Reiterated
Buy → Buy 2026-02-23 20% win rate (5 calls)
Barclays — Reiterated
Overweight → Overweight 2025-12-17 Building track record
TD Cowen ● Initiated
Buy 2025-12-02 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2025-09-23 Building track record
Barclays — Reiterated
Overweight → Overweight 2025-09-23 Building track record
Stephens & Co. reit
Overweight → Overweight 2025-09-22 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →